Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2013-09-18 Capital/Financing Update
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 18, 2013, reporting the closing of a public offering. It includes references to a press release and a warrant agreement related to the offering. The content focuses on the completion of a financing event rather than financial results or management discussion. The document length is short (2919 characters) and primarily announces the closing of a financing transaction. This fits the category of Capital/Financing Update (CAP) rather than a full financial report or other categories.
2013-09-18 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an offering of common stock and warrants. It includes detailed information about the securities being offered, underwriting, risk factors, use of proceeds, and company overview. The document is a formal offering document used in capital raising activities, specifically describing terms of a securities offering. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual or quarterly report, audit report, or any other type of filing. It is not a report publication announcement or a regulatory filing in the fallback category because it contains substantive offering details. Therefore, the correct classification is CAP with high confidence.
2013-09-13 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 13, 2013, by Galena Biopharma, Inc. It details the entry into a material definitive agreement related to a public offering of units consisting of common stock and warrants. The document includes specifics about the underwriting agreement, pricing, number of shares, and related legal opinions. There is no financial statement or quarterly/annual report data included, nor is it a transcript or management discussion. The content focuses on a financing event and capital raising activity. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (8505 characters) and detailed description of the offering support this classification with high confidence.
2013-09-13 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a Preliminary Prospectus Supplement filed pursuant to Rule 424(b)(5) related to a securities offering, specifically involving common stock and warrants. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company background. The document references SEC registration numbers and is clearly a filing related to capital raising activities. It is not a financial report, earnings release, or management discussion, but rather a disclosure document for a securities offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual prospectus supplement, not just an announcement of a report.
2013-09-12 English
Regulatory Filings 2013
Regulatory Filings
2013-08-16 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the offering and sale of common stock and warrants. It includes detailed information about the securities offered, risk factors, use of proceeds, dilution, description of securities, selling securityholders, and plan of distribution. The presence of terms like 'prospectus', 'offering', 'selling securityholders', 'plan of distribution', and references to SEC registration and Rule 424(b)(3) indicate this is a capital raising document. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual or interim report, earnings release, or any other report type but a financing prospectus. Therefore, the correct classification is CAP with high confidence.
2013-08-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.